ACER3 deficiency is a very rare, inherited brain white-matter disease. It starts in infancy and slowly gets worse over time. Children first stop gaining new skills and then lose skills they already learned. Speech and movement are affected early. Over time, most children cannot communicate or move with purpose. The problem happens because changes (mutations) in the ACER3 gene make the alkaline ceramidase-3 enzyme work poorly or not at all. This enzyme normally helps break down ceramide (a fat molecule) into sphingosine, which then becomes sphingosine-1-phosphate. These “sphingolipids” are important building blocks and signals for myelin (the white coating that protects nerves) and for brain cell health. When ACER3 does not work, ceramide balance is disturbed, myelin does not form or keep healthy, and white matter in the brain is damaged. This is why the condition is a leukodystrophy (a disease of white matter). PMC+2MDPI+2
Leukodystrophy due to ACER3 deficiency is a rare, inherited brain disorder that starts in infancy or early childhood. It harms the white matter of the brain (the wiring made of myelin). Children first stop making expected progress and then lose skills they already had. They may lose the ability to sit, stand, walk, or speak, and later may not communicate or move on purpose. Doctors often see low muscle tone in the body’s core, stiff or tight limbs, abnormal movements, vision problems from damage to the optic nerve, nerve damage in the legs and arms, and bladder problems caused by nerve signals not working well. This condition happens because both copies of a gene called ACER3 are altered. ACER3 normally breaks down certain fats (ceramides) inside cells; when ACER3 does not work, these fats build up and disturb myelin and nerve health. Genetic Diseases Info Center+2PMC+2
Other names
Doctors and databases may use several names for the same condition:
ACER3-related early childhood-onset progressive leukodystrophy
ACER3-related leukoencephalopathy
Leukodystrophy due to alkaline ceramidase 3 deficiency
Alkaline ceramidase 3 deficiency
PLDECO (Progressive Leukodystrophy, Early Childhood-Onset; OMIM #617762)
These labels all point to the same disease involving ACER3. National Organization for Rare Disorders+2Orpha+2
Types
Because this disease is very rare, only a small number of families have been reported. Doctors describe a spectrum rather than strict subtypes:
Classic infantile-onset progressive leukodystrophy. Onset at about 6–13 months with developmental slowing, then regression (loss of motor and language skills), low trunk tone, stiff limbs, abnormal movements, vision problems (optic disc pallor), peripheral neuropathy, and neurogenic bladder. MRI shows widespread white-matter disease. PMC+1
Early-childhood onset with added features. Similar to the classic form but reports also note seizures and some variation in MRI patterns (such as delayed myelination or evolving changes). PMC
At this time there is no confirmed adult-onset form of ACER3 leukodystrophy in the medical literature; the condition is understood as an infancy/early-childhood disease. PMC+1
Causes
The single root cause is pathogenic (harmful) variants in both copies of the ACER3 gene, inherited in an autosomal recessive way. Below are 20 plain-language “cause items” that together explain what causes it and why it looks the way it does:
Biallelic ACER3 variants. A child inherits one non-working ACER3 from each parent. This is the fundamental cause. PubMed
Loss of ACER3 enzyme activity. The enzyme fails to break down certain unsaturated long-chain ceramides. ScienceDirect
Ceramide accumulation and sphingolipid imbalance. Harmful buildup disrupts cell membranes and signals. MDPI+1
Myelin vulnerability. Oligodendrocytes (myelin-making cells) are sensitive to sphingolipid imbalance → white-matter injury. JLR
Neuronal stress and apoptosis. Abnormal ceramides can push cells toward stress and programmed cell death. Cell
Missense variants (protein change). Some families have single-letter changes (for example Glu33Gly) that damage function. marrvel.org
Nonsense/frameshift variants. “Stop” or frameshift changes can make ACER3 very short or absent. (Mechanism inferred from general genetics plus reported families.) PubMed
Splice-site variants. Changes that alter how RNA is spliced may remove or distort enzyme parts. (Mechanism consistent with rare-disease genetics.) PubMed
Homozygosity/consanguinity. Parents who are related may carry the same rare variant, increasing risk in children. (General recessive inheritance principle applied to ACER3 reports.) PubMed
Developmental timing. Infancy is a period of rapid myelination; enzyme failure during this window leads to early regression. PMC
Peripheral nerve myelin involvement. Sural nerve biopsy in reported cases shows hypomyelination. Genetic Diseases Info Center
Optic pathway involvement. Optic nerve fibers can degenerate (optic disc pallor/atrophy). Genetic Diseases Info Center
Spinal and bladder pathway involvement. Damage to tracts controlling bladder leads to neurogenic bladder. Genetic Diseases Info Center
Variant-specific severity. Different mutations may change how early and how severely symptoms appear (not all families show identical MRI or clinical patterns). BioMed Central
Secondary inflammation or glial stress. Sphingolipid imbalance can trigger inflammatory pathways that worsen myelin injury. (Shown broadly in sphingolipid literature.) Cell
Energy and axonal transport stress. Myelin damage strains long axons, adding to weakness and spasticity. (General leukodystrophy mechanism.) JLR
Impaired sphingosine/S1P signaling balance. ACER3 defects alter the ceramide ↔ sphingosine balance that guides cell survival and differentiation. MDPI
White-matter network disconnection. Widespread myelin injury disconnects brain networks, driving loss of movement and language. PMC
No environmental cause. Infections, diet, or injuries do not cause ACER3 leukodystrophy; it is genetic, though illnesses can temporarily worsen symptoms. Genetic Diseases Info Center
Ultra-rarity itself. Very few families are known, which is why knowledge is still growing and patterns keep expanding as new cases are reported. BioMed Central
Symptoms and signs
Developmental stagnation – progress slows or stops after a period of normal early milestones. Genetic Diseases Info Center
Developmental regression – loss of skills: sitting, standing, walking, or talking may be lost over time. Genetic Diseases Info Center
Loss of language and communication – speech fades and purposeful interaction may stop. Genetic Diseases Info Center
Truncal hypotonia – low tone in the body’s core; the child feels “floppy” in trunk/neck. PMC
Appendicular spasticity – arms and legs become stiff and tight; increased reflexes may appear. PMC
Dystonia or abnormal movements – twisting or repetitive postures or jerky movements. PMC
Peripheral neuropathy – nerve damage in limbs causing weakness, reduced reflexes or sensation changes. Genetic Diseases Info Center
Neurogenic bladder – trouble storing or emptying urine because of damaged nerve pathways. Genetic Diseases Info Center
Optic disc pallor/optic atrophy – pale optic nerves leading to reduced vision. Genetic Diseases Info Center
Feeding difficulties and failure to thrive – poor swallowing, weight loss, or growth concerns can appear as skills regress. (Common across severe infantile leukodystrophies; also consistent with ACER3 case descriptions.) PMC
Abnormal startle or irritability – can reflect white-matter dysfunction in infancy. (General leukodystrophy observation; added cases broaden features.) BioMed Central
Seizures – not in all children, but reported in expanded case series. PMC
Contractures over time – long-term stiffness can shorten muscles and tendons. (Secondary to spasticity in progressive leukodystrophies.) PMC
Breathing or swallowing coordination problems – later in the disease course, brainstem pathways can be affected. (General leukodystrophy evolution; severity varies.) JLR
Global loss of purposeful movement – in advanced stages many purposeful actions stop. Genetic Diseases Info Center
Diagnostic tests
A. Physical examination (at the bedside)
Full neurological exam. Checks tone, strength, reflexes, coordination, eye movements, and sensation. In ACER3 leukodystrophy, doctors often find low trunk tone, stiff limbs, brisk reflexes, dystonia, and sometimes reduced distal reflexes from neuropathy. PMC
Developmental assessment. Compares skills to age norms; documents slowing and regression in motor and language domains. Genetic Diseases Info Center
Vision and eye exam (pupils, tracking, fundus). Can show optic disc pallor and reduced fixation/visual responses. Genetic Diseases Info Center
Bladder function screening. History of urgency, leakage, retention; abdominal palpation; perineal reflexes—flags neurogenic bladder for further testing. Genetic Diseases Info Center
Growth and nutrition check. Weight, length, head size, hydration, and swallow safety screening to guide support in a progressive disorder. (Standard care in infantile leukodystrophies.) JLR
B. Manual/bedside functional tests
Head-lag (“pull-to-sit”) test. Shows low trunk/neck tone in infants when head control is lost. (Common pediatric bedside sign in hypotonia.) PMC
Postural tone and scissoring check. Gentle passive movements revealing limb stiffness or scissoring, typical in spasticity. PMC
Primitive reflex persistence. Looking for Moro, grasp, tonic neck reflexes beyond expected ages—often seen when white matter is damaged. (General pediatric neurology principle.) JLR
Visual fixation and tracking. Bedside check for ability to fix on faces/objects and track—often reduced in optic pathway involvement. Genetic Diseases Info Center
Bedside bladder diary/residual check (pre-urodynamics). Timed voiding diary and ultrasound residual estimate can flag significant dysfunction. (Screen leading to formal testing.) PM&R KnowledgeNow
C. Laboratory and pathological tests
Genetic testing (ACER3 sequencing or exome/genome). Confirms two disease-causing variants; this is the definitive test. Laboratories can report known variants (e.g., Glu33Gly) or novel ones. marrvel.org
Sphingolipid profiling (plasma/fibroblast LC-MS). Measures ceramides and related lipids; ACER3 loss skews this balance and supports the diagnosis. MDPI
ACER3 enzyme activity (research/advanced labs). Functional assays in patient cells can show low ceramidase activity. ScienceDirect
Sural nerve biopsy (when needed). Can show reduced myelination in peripheral nerves, matching clinical neuropathy. Genetic Diseases Info Center
Basic metabolic work-up to exclude mimics. Standard blood/CSF tests help rule out treats-first conditions and other leukodystrophies before genetics are back. (Good clinical practice for white-matter disease.) JLR
D. Electrodiagnostic tests
Electromyography/nerve conduction studies (EMG/NCS). Detects peripheral neuropathy (slow conduction, low amplitudes) that can accompany ACER3 deficiency. Genetic Diseases Info Center
Electroencephalogram (EEG). Looks for seizure activity when events or regression suggest epilepsy; seizures have been reported in some patients. PMC
Evoked potentials (VEP, BAEP, SSEP). Measure pathway function from eye, ear, or limbs to brain; can show slowed conduction in demyelinated tracts. (Widely used in leukodystrophies.) JLR
E. Imaging tests
Brain MRI (core test). Shows diffuse white-matter disease and delayed myelination patterns; helps separate leukodystrophy from other causes. Serial MRIs track progression. PMC+1
Spinal MRI and targeted imaging when indicated. May be used to assess cord tracts or to evaluate other causes of spasticity and bladder dysfunction, complementing brain findings. (General leukodystrophy assessment practice.) JLR
Non-pharmacological treatments (therapies & supports)
Note: These do not cure the disease. They aim to preserve function, reduce complications, and improve comfort and participation. Use a multidisciplinary team (neurology, physiatry, PT/OT/SLT, nutrition, palliative care).
Physiotherapy for posture and tone — Daily gentle stretching, range-of-motion, positioning, and supported sitting help prevent contractures and scoliosis and ease caregiving. Purpose: keep joints flexible; Mechanism: sustained muscle-tendon lengthening and neuroplastic practice.
Spasticity management program — Heat packs, stretching schedules, proper seating, and orthoses to reduce stiffness and pain. Purpose: reduce spasms and improve comfort; Mechanism: lowers muscle spindle hyperactivity through prolonged stretch and external support.
Occupational therapy (OT) — Adaptive seating, hand splints, switch access, and environmental controls. Purpose: maintain daily routines; Mechanism: compensates for motor loss by optimizing task-environment fit.
Speech-language therapy (SLT) — Oral-motor care, swallowing strategies, secretion control, and early augmentative and alternative communication (AAC) (eye-gaze boards, switches). Purpose: keep safe feeding and enable communication; Mechanism: compensatory techniques + assistive tech.
Feeding and nutrition support — Texture modification, slow-flow nipples, upright positioning; if unsafe or insufficient, consider gastrostomy (below) for long-term nutrition. Purpose: prevent malnutrition/aspiration; Mechanism: reduces choking risk and maintains calories.
Respiratory hygiene — Chest physiotherapy, suctioning guidance, positioning, and vaccinations (per schedule). Purpose: reduce lung infections; Mechanism: improves airway clearance.
Seizure first-aid education — Family training on safe positioning, timing episodes, and when to call emergency care. Purpose: safety; Mechanism: rapid, appropriate response.
Vision rehabilitation — Low-vision strategies if optic pallor/visual impairment: contrast-rich materials, lighting, and orientation techniques. Purpose: maximize remaining vision; Mechanism: environmental optimization.
Hearing evaluation & aids — Early screening and amplification if needed to support communication. Purpose: improve input; Mechanism: assistive amplification.
Orthoses & seating systems — AFOs, knee-ankle-foot orthoses, and custom wheelchairs with head supports. Purpose: prevent deformity and improve positioning; Mechanism: biomechanical alignment.
Scoliosis surveillance & bracing — Regular spine checks; bracing if indicated. Purpose: slow curve progression; Mechanism: external corrective forces.
Bone health program — Weight-bearing with standers, vitamin D/calcium intake, and fracture prevention. Purpose: avoid osteoporosis; Mechanism: mechanical loading of bones.
Bladder & bowel routines — Timed voiding, diapers/catheters if neurogenic bladder, constipation prevention with fluids/fiber and routines. Purpose: prevent infections and discomfort; Mechanism: behavioral schedules + aids.
Skin integrity care — Pressure relief schedules, cushions, and moisture control. Purpose: prevent pressure ulcers; Mechanism: off-loading and barrier protection.
Pain & comfort plan (non-drug) — Warm baths, massage, gentle ROM, and calm sensory environments. Purpose: reduce distress; Mechanism: activates non-nociceptive pathways and relaxation.
Education plan & early intervention — Individualized education program with therapies embedded. Purpose: maximize developmental stimulation; Mechanism: structured, repeated practice.
Palliative care (early) — Symptom control, decision support, and family goals-of-care. Purpose: quality of life; Mechanism: coordinated supportive care.
Caregiver training & respite — Teach safe transfers, feeding, seizure response; arrange respite services. Purpose: reduce caregiver burnout; Mechanism: skill-building + rest.
Infection prevention habits — Hand hygiene, oral care, vaccinations as advised; prompt care for fevers. Purpose: avoid complications; Mechanism: decreases pathogen exposure.
Genetic counseling — Explain inheritance (usually autosomal recessive), carrier testing, and prenatal options. Purpose: informed family planning; Mechanism: risk assessment and counseling. Genetic Diseases Info Center+1
Drug treatments
There is no established disease-modifying medicine for ACER3 deficiency as of today; management is supportive. Doses below are typical references used by clinicians in similar conditions and must be individualized by a specialist—especially for infants/children. Do not start, stop, or change any medicine without your doctor. ScienceDirect
Baclofen (oral/enteral) — Class: antispasticity (GABA_B agonist). Typical adult: 5–20 mg three times daily; pediatric often 0.5–2 mg/kg/day divided. Purpose: reduce spasticity; Mechanism: decreases excitatory neurotransmission in spinal cord. Side effects: sleepiness, weakness.
Tizanidine — α2-adrenergic agonist. Adult: 2–4 mg up to TID; pediatric specialist dosing only. Purpose: spasticity relief; Side effects: sedation, low blood pressure, elevated LFTs.
Diazepam (spasticity/acute spasms) — Benzodiazepine. Dose: individualized; Purpose: muscle relaxation; Side effects: sedation, respiratory depression risk.
Intrathecal baclofen — Pump-delivered antispasticity in refractory cases (drug + procedure). Purpose: strong tone control; Risks: infection, withdrawal if pump fails.
Botulinum toxin injections — Local chemodenervation for focal spasticity/dystonia. Dose: per muscle pattern. Purpose: ease care, improve comfort; Side effects: local weakness.
Levetiracetam — Antiseizure. Adults: 500–1500 mg BID; pediatric weight-based. Purpose: control seizures; Mechanism: SV2A modulation. Side effects: mood changes, somnolence.
Valproate — Broad antiseizure. Dose: weight-based; monitor LFTs/platelets. Side effects: liver/pancreas toxicity risk, weight gain, teratogenicity (avoid in pregnancy).
Clobazam / Clonazepam — Benzodiazepines for seizures/myoclonus. Side effects: sedation, tolerance.
Oxcarbazepine / Carbamazepine — Focal seizures; watch sodium (hyponatremia) and drug interactions.
Topiramate — Add-on broad antiseizure; side effects: appetite loss, cognitive slowing, kidney stones.
Phenobarbital — Neonatal/infant seizures; sedating; monitor levels.
Trihexyphenidyl — Anticholinergic for dystonia; Side effects: dry mouth, constipation, confusion (higher doses).
Gabapentin — Neuropathic pain/spasticity adjunct; Side effects: sedation, dizziness.
Melatonin — Sleep dysregulation; 1–5 mg (children often lower; titrate). Side effects: daytime sleepiness.
Glycopyrrolate — Reduces drooling/secretions; Side effects: constipation, dry mouth.
Proton-pump inhibitor (e.g., omeprazole) — For reflux from poor tone/posture; Side effects: diarrhea, hypomagnesemia with long use.
Laxatives (PEG 3350) — Constipation management; Side effects: bloating, cramps.
Antibiotics per culture — For pneumonia/UTIs when present; follow stewardship.
Anticholinergics (oxybutynin) or intermittent catheterization — For neurogenic bladder; Side effects: dry mouth, constipation.
Vitamin D + Calcium (when deficient) — Bone health with weight-bearing. Side effects: hypercalcemia if overdosed.
(These choices reflect standard symptomatic neurology/rehab care in pediatric leukodystrophies; high-quality randomized trials specific to ACER3 are not yet available.)
Dietary & molecular supplements
None are proven to change the course of ACER3 deficiency; they are considered supportive when deficiencies or specific goals exist.
Vitamin D3 — Dose as per level/age. Function: bone health, immune modulation; Mechanism: calcium/phosphate balance.
Calcium — If dietary intake is low. Function: bone strength.
Omega-3 fatty acids (DHA/EPA) — May support neuronal membranes; Mechanism: anti-inflammatory lipid mediators.
Choline — Membrane phospholipid precursor; may support myelin lipid pools.
Creatine — Energy buffer in muscle/brain; use cautiously; evidence mixed.
Coenzyme Q10 — Mitochondrial cofactor; antioxidant role.
Multivitamin with iron/trace elements — If dietary variety is limited.
Probiotics — Gut health; may reduce antibiotic-associated diarrhea.
Magnesium — If deficient; may help cramps/constipation.
Fiber supplements — Constipation prevention.
(These are general neuro-nutrition principles; no ACER3-specific outcome data.)
Immunity-booster / regenerative / stem-cell–type” drug concepts
Important: These are theoretical or experimental directions from broader sphingolipid biology and myelin repair research. They are not approved for ACER3 deficiency, and participation would generally require a clinical trial. Current literature notes no established therapy for ACER3. ScienceDirect
Substrate modulation of sphingolipids — Small molecules that adjust ceramide/sphingosine balance to protect myelin. Concept drawn from ceramide-pathway studies. PMC+1
S1P-pathway modulators — Agents that influence sphingosine-1-phosphate signaling (conceptual; off-label risks are significant). Goal: support oligodendrocyte survival/myelination.
Antioxidant/anti-apoptotic cocktails — Target lipid-stress injury; only supportive evidence.
Gene therapy — Delivering a correct ACER3 copy to brain cells (no clinical program yet known for ACER3).
Allogeneic hematopoietic stem-cell transplantation (HSCT) — Used in some leukodystrophies (e.g., Krabbe/ALD) very early; not established for ACER3.
Cell-based myelin repair (oligodendrocyte progenitors) — Pre-clinical in leukodystrophies; not available as routine care.
(Families should ask about natural-history or registry studies and check clinical-trial registries.) ClinicalTrials.gov
Surgeries/procedures
Gastrostomy (G-tube) — When swallowing is unsafe or intake is inadequate. Why: secure hydration/nutrition; reduce aspiration risk.
Intrathecal baclofen pump implantation — For severe, generalized spasticity not controlled by oral drugs. Why: stronger tone control with fewer systemic effects.
Orthopedic soft-tissue releases — For fixed contractures that cause pain or hygiene problems. Why: improve positioning and care.
Scoliosis surgery (spinal fusion) — For severe, progressive curves affecting sitting/respiration. Why: stabilize spine, ease care, help breathing.
Airway procedures (tracheostomy) in severe cases — If chronic aspiration/airway protection fails. Why: airway security and ventilation support.
Preventions
Keep vaccinations up to date (per physician advice).
Hand hygiene and oral care to lower infection risk.
Safe feeding plans to prevent aspiration.
Daily stretching/positioning to avoid contractures.
Pressure-relief schedules and cushions for skin health.
Weight-bearing/stander time and bone nutrients.
Early treatment of constipation and reflux.
Seizure safety plan and medication adherence.
Regular equipment checks (orthoses, wheelchairs).
Seasonal respiratory precautions (masking in outbreaks as advised).
When to see doctors (red flags)
New or worsening seizures, changes in breathing, feeding, or arousal.
Repeated choking, weight loss, dehydration, or pneumonia signs.
Uncontrolled pain or severe spasticity/dystonia.
Pressure sores, skin breakdown, or unexplained fevers.
Rapid curve of the spine, hip dislocation signs (asymmetry, pain).
Any sudden regression of skills beyond the expected course.
For families: anytime you need help adjusting equipment, meds, or supports.
What to eat and what to avoid
What to eat: balanced, calorie-adequate meals that are easy to swallow—smooth purees, soft textures, adequate protein, healthy fats (including omega-3 sources), fiber, and fluids. If oral intake is not safe or enough, use clinician-guided formulas by mouth or G-tube.
What to avoid: foods that are hard, dry, or crumbly if swallowing is unsafe; thin liquids if advised to thicken; very acidic or spicy foods if reflux worsens; excess sugar/salt; unproven supplements that may interact with medicines. Always personalize with a dietitian.
FAQs
How common is ACER3 deficiency? Extremely rare; only a small number of families worldwide have been reported. Orpha+1
When do symptoms start? Usually in infancy (around 6–13 months) with stagnation then regression. PMC
What are early signs? Low trunk tone, stiff limbs, feeding problems, delayed or lost milestones. Genetic Diseases Info Center
How is it diagnosed? Genetic testing for ACER3 variants plus brain MRI showing white-matter disease/hypomyelination; sometimes nerve studies/biopsy. PMC
Is there a cure? Not yet; no proven disease-modifying therapy. Care is supportive. ScienceDirect
Why does myelin fail? Disrupted sphingolipid balance from missing ACER3 harms myelin and neurons. PMC
Can diet fix it? Diet supports health and safety but cannot replace ACER3 enzyme function.
Are there clinical trials? None specific to ACER3 were readily identified in major registries at this time; ask your center to re-check periodically. ClinicalTrials.gov
Could HSCT help? It helps some other leukodystrophies when done very early; it is not established for ACER3.
Will seizures occur? Some children have seizures; antiseizure medicines can help control them. Genetic Diseases Info Center
What about vision? Optic disc pallor and vision problems may occur; involve low-vision and neurology teams. Genetic Diseases Info Center
Is it inherited? Often autosomal recessive—each parent is usually a healthy carrier. Genetic counseling is recommended. PMC
What does MRI show? Leukoencephalopathy/hypomyelination consistent with leukodystrophy. PMC
What research gives hope? Basic science on ceramidases and sphingolipid signaling suggests targets for future therapies. PMC+1
Where to learn more? Orphanet and GARD have family-friendly summaries; ask your care team for reputable registries. Orpha+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 12, 2025.
